Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29
Titel:
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29
Auteur:
Chapman, Judith-Anne W. Costantino, Joseph P. Dong, Bin Margolese, Richard G. Pritchard, Kathleen I. Shepherd, Lois E. Gelmon, Karen A. Wolmark, Norman Pollak, Michael N.